This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
What the researchers found
Semaglutide reduced the risk of major adverse cardiovascular events (MACE) with hazard ratios of 0.70 for metformin users and 0.86 for non-users.
Why it matters
Understanding how semaglutide works for different patient groups can help tailor diabetes treatments and improve heart health outcomes. This could lead to better management strategies for patients at high cardiovascular risk.
How the study worked
The study involved a post hoc analysis of pooled data from the SUSTAIN 6 and PIONEER 6 trials, along with a meta-analysis of seven cardiovascular outcome trials.
What this study cannot tell us
The analysis is based on post hoc data, which may limit the strength of the conclusions. Additionally, the study population may not represent all diabetes patients.
Read the original research
Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.
Cardiovascular diabetology, 21(1), 64
Citation
Husain, Mansoor; Consoli, Agostino; De Remigis, Alessandra; Pettersson Meyer, Anna Sina; Rasmussen, Søren; Bain, Stephen. (2022). Semaglutide reduces cardiovascular events regardless of metformin use: a post hoc subgroup analysis of SUSTAIN 6 and PIONEER 6.. Cardiovascular diabetology, 21(1), 64. https://doi.org/10.1186/s12933-022-01489-6